))
Data Science in Drug Development: Evaluate’s Jon Moser on what biopharma learnt about data science in 2020
Manage episode 353779827 series 3442226
Content provided by Hg. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Hg or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The COVID-19 pandemic has been incredibly disruptive for people all across the world, but has really thrown the spotlight on pharma companies. We’ve seen drugs designed and developed in record times. We’ve seen more collaboration between scientists, pharma companies and regulators than ever before – collaboration that has seen sharing of science, approaches and data. This has accelerated an ongoing trend in pharma, as pharma companies have become more and more data-centric and data-savvy. In this episode, Hg’s Amr Ellabban speaks with Jon Moser, SVP, Innovation, Research & Development at Evaluate, and explains how biopharma’s approach to data science has changed and what we’re likely to see going forward. Evaluate is a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry. Hg first invested in Evaluate in 2016.
…
continue reading
37 episodes
Share
